The Interplay Between Accumulation of Amyloid-Beta and Tau Proteins, PANoptosis, and Inflammation in Alzheimer’s Disease

被引:1
|
作者
Xianbo Zhuang [1 ]
Jie Lin [2 ]
Yamin Song [3 ]
Ru Ban [1 ]
Xin Zhao [1 ]
Zhangyong Xia [1 ]
Zheng Wang [1 ]
Guifeng Zhang [4 ]
机构
[1] Department of Neurology, Liaocheng People’s Hospital and Liaocheng Hospital Affiliated to Shandong First Medical University, Liaocheng
[2] School of Basic Medicine Sciences, Shandong University, Jinan
[3] Department of Joint Laboratory for Translational Medicine Research, Liaocheng People’s Hospital, Liaocheng
[4] Department of Neurology, Liaocheng People’s Hospital, Shandong University, Jinan
[5] Department of Neurology, the Second People’s Hospital of Liaocheng, Liaocheng
[6] Department of Neurosurgery, Liaocheng Traditional Chinese Medicine Hospital, Liaocheng
关键词
Alzheimer’s disease; Amyloid-beta; Inflammation; PANoptosis; Tau protein; Therapeutic strategy;
D O I
10.1007/s12017-024-08815-z
中图分类号
学科分类号
摘要
Alzheimer’s disease (AD) is a common progressive neurodegenerative disorder, and the vast majority of cases occur in elderly patients. Recently, the accumulation of Aβ and tau proteins has drawn considerable attention in AD research. This review explores the multifaceted interactions between these proteins and their contribution to the pathological landscape of AD, encompassing synaptic dysfunction, neuroinflammation, and PANoptosis. PANoptosis is a collective term for programmed cell death (PCD) modalities that encompass elements of apoptosis, pyroptosis, and necroptosis. The accumulation of Aβ peptides and tau proteins, along with the immune response in brain cells, may trigger PANoptosis, thus advancing the progression of the disease. Recent advancements in molecular imaging and genetics have provided deeper insights into the interactions between Aβ peptides, tau proteins, and the immune response. The review also discusses the role of mitochondrial dysregulation in AD. The exploration of the interplay between neurodegeneration, immune responses, and cell death offers promising avenues for the development of innovative treatments. © The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2024.
引用
收藏
相关论文
共 50 条
  • [21] Relationship between amyloid-beta and the ubiquitin-proteasome system in Alzheimer's disease
    Hong, Liang
    Huang, Han-Chang
    Jiang, Zhao-Feng
    NEUROLOGICAL RESEARCH, 2014, 36 (03) : 276 - 282
  • [22] The relationship between amyloid-beta and brain capillary endothelial cells in Alzheimer's disease
    Zhang, Yan-Li
    Wang, Juan
    Zhang, Zhi-Na
    Su, Qiang
    Guo, Jun-Hong
    NEURAL REGENERATION RESEARCH, 2022, 17 (11) : 2355 - 2363
  • [23] In Silico Drug Design and Analysis of Dual Amyloid-Beta and Tau Protein-Aggregation Inhibitors for Alzheimer's Disease Treatment
    Job, Nisha
    Thimmakondu, Venkatesan S. S.
    Thirumoorthy, Krishnan
    MOLECULES, 2023, 28 (03):
  • [24] Amyloid-beta and Alzheimer's disease: the role of neprilysin-2 in amyloid-beta clearance
    Marr, Robert A.
    Hafez, Daniel M.
    FRONTIERS IN AGING NEUROSCIENCE, 2014, 6
  • [25] Mass spectrometry analysis of tau and amyloid-beta in iPSC-derived models of Alzheimer's disease and dementia
    Arber, Charles
    Alatza, Argyro
    Leckey, Claire A.
    Paterson, Ross W.
    Zetterberg, Henrik
    Wray, Selina
    JOURNAL OF NEUROCHEMISTRY, 2021, 159 (02) : 305 - 317
  • [26] Carbon dots as dual inhibitors of tau and amyloid-beta aggregation for the treatment of Alzheimer's disease
    Zhang, Wei
    Smith, Nathan
    Zhou, Yiqun
    McGee, Caitlin M.
    Bartoli, Mattia
    Fu, Shiwei
    Chen, Jiuyan
    Domena, Justin B.
    Joji, Annu
    Burr, Hannah
    Lv, Guohua
    Cilingir, Emel K.
    Bedendo, Susanna
    Claure, Matteo L.
    Tagliaferro, Alberto
    Eliezer, David
    Veliz, Eduardo A.
    Zhang, Fuwu
    Wang, Chunyu
    Leblanc, Roger M.
    ACTA BIOMATERIALIA, 2024, 183 : 341 - 355
  • [27] Plasma Amyloid-Beta Levels in Korean Patients with Alzheimer's Disease
    Cho, Sun Young
    Kang, So Young
    Lee, Woo In
    CLINICAL LABORATORY, 2016, 62 (08) : 1591 - 1593
  • [28] Pyroglutamate and Isoaspartate modified Amyloid-Beta in ageing and Alzheimer’s disease
    Maria Luisa Moro
    Andrew Stephen Phillips
    Katie Gaimster
    Christian Paul
    Amritpal Mudher
    James A. R. Nicoll
    Delphine Boche
    Acta Neuropathologica Communications, 6
  • [29] Lipid peroxidation and Alzheimer's disease: Key role of Amyloid-beta
    Kontush, Anatol
    OCL-OILSEEDS AND FATS CROPS AND LIPIDS, 2006, 13 (01) : 46 - 53
  • [30] Amyloid-beta aggregation implicates multiple pathways in Alzheimer's disease: Understanding the mechanisms
    Iliyasu, Musa O.
    Musa, Sunday A.
    Oladele, Sunday B.
    Iliya, Abdullahi I.
    FRONTIERS IN NEUROSCIENCE, 2023, 17